Connect Biopharma Holdings Limited (CNTB): Price and Financial Metrics

Connect Biopharma Holdings Limited (CNTB): $0.91

0.03 (+3.81%)

POWR Rating

Component Grades













Add CNTB to Watchlist
Sign Up

Industry: Biotech



in industry

CNTB Stock Price Chart Interactive Chart >

Price chart for CNTB

CNTB Price/Volume Stats

Current price $0.91 52-week high $29.27
Prev. close $0.88 52-week low $0.56
Day low $0.83 Volume 498,900
Day high $1.02 Avg. volume 281,060
50-day MA $2.35 Dividend yield N/A
200-day MA $9.63 Market Cap 50.12M

Connect Biopharma Holdings Limited (CNTB) Company Bio

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

CNTB Latest News Stream

Event/Time News Detail
Loading, please wait...

CNTB Latest Social Stream

Loading social stream, please wait...

View Full CNTB Social Stream

Latest CNTB News From Around the Web

Below are the latest news stories about Connect Biopharma Holdings Ltd that investors may wish to consider to help them evaluate CNTB as an investment opportunity.

Connect Biopharma (CNTB) presents at SVB Leerink 11th Annual Global Healthcare Conference - Slideshow

No summary available.

Seeking Alpha | February 17, 2022

Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 4:20 pm ET.

GlobeNewswire | February 9, 2022

Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference

—Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo —Analyses demonstrate that the benefits of CBP-201 to patients continue to increase as baseline disease severity increases — —Data and analyses support the potential for a highly competitive efficacy and safety profile for CBP-201 that includes a differentiated Q4W dosing schedule — SAN DIEGO, C

Yahoo | January 24, 2022

Connect Biopharma''s Latest Dermatitis Drug Update Fails To Pump Up Shares

No summary available.

Seeking Alpha | January 12, 2022

Leerink Partners Thinks Connect Biopharma Holdings’ Stock is Going to Recover

In a report released today, Thomas Smith from Leerink Partners maintained a Buy rating on Connect Biopharma Holdings (CNTB – Research Report), with a price target of $22.00. The company's shares closed last Wednesday at $5.00, close to its 52-week low of $4.10. According to, Smith has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.3% and a 21.4% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Prometheus Biosciences, and Eledon Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Connect Biopharma Holdings.

Christine Brown on TipRanks | January 6, 2022

Read More 'CNTB' Stories Here

CNTB Price Returns

1-mo -66.30%
3-mo N/A
6-mo -78.98%
1-year -94.14%
3-year N/A
5-year N/A
YTD -82.33%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6501 seconds.